Biofrontera AG
BIFRF
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 03/31/2025 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.26M | 955.70K | 4.16M | 3.45M | 13.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.26M | 955.70K | 4.16M | 3.45M | 13.05M |
| Cost of Revenue | 813.60K | -1.37M | 1.35M | 623.00K | 2.52M |
| Gross Profit | 3.45M | 2.32M | 2.81M | 2.82M | 10.53M |
| SG&A Expenses | 2.82M | 4.50M | 2.57M | 2.46M | 3.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.25M | 2.30M | 5.33M | 3.67M | 8.64M |
| Operating Income | 10.30K | -1.35M | -1.17M | -225.20K | 4.41M |
| Income Before Tax | 47.10K | -2.70M | -431.40K | -237.80K | 1.32M |
| Income Tax Expenses | -- | 634.20K | 1.20K | -- | 965.50K |
| Earnings from Continuing Operations | 47.10K | -3.33M | -432.60K | -237.80K | 359.20K |
| Earnings from Discontinued Operations | 2.48M | -- | -- | 951.30K | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.52M | 134.50K | -432.60K | 713.50K | 359.20K |
| EBIT | 10.30K | -1.35M | -1.17M | -225.20K | 4.41M |
| EBITDA | 62.80K | -1.35M | -1.10M | -161.50K | 4.62M |
| EPS Basic | 0.41 | 0.02 | -0.07 | 0.12 | 0.13 |
| Normalized Basic EPS | 0.00 | -0.28 | -0.04 | -0.02 | 0.31 |
| EPS Diluted | 0.41 | 0.02 | -0.07 | 0.12 | 0.13 |
| Normalized Diluted EPS | 0.00 | -0.28 | -0.04 | -0.02 | 0.31 |
| Average Basic Shares Outstanding | 6.11M | 6.08M | 6.17M | 6.16M | 2.68M |
| Average Diluted Shares Outstanding | 6.11M | 6.08M | 6.17M | 6.16M | 2.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |